Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.
One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.
Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.
Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.
Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.
For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
Ginkgo Bioworks (NYSE: DNA) announced that its Ginkgo Automation division will design and deploy a flexible laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC) at the University of Wisconsin–Madison. The system aims to support biofuels and bioproducts research from plant biomass.
The new anaerobic-capable automation system will enable GLBRC scientists to run multiple experiments simultaneously across both aerotolerant and anaerobic conditions, increasing efficiency and 'walkaway' time. The system includes access to Catalyst Flow, a remote error resolution service expected to resolve 80-90% of system errors without user intervention.
Built on expertise from Ginkgo Bioworks and Zymergen, the customizable system focuses on automating workflows for anaerobic organisms, a key requirement for GLBRC's research programs. The technology aims to help GLBRC advance its mission of enabling cost-effective, sustainable biofuel production at scale.
Ginkgo Bioworks (NYSE: DNA) has announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. The partnership aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics for solid tumors.
The collaboration combines Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in design and screening large CAR libraries and its high-throughput, multimodal immune cell engineering platform. Ginkgo's approach utilizes computational tools, library assembly and screening expertise, and statistical analysis to accelerate therapeutic design optimization.
The platform enables simultaneous testing of numerous CAR designs from transcriptome to cell function, focusing on improving immune cell persistence and functionality. This partnership represents a significant expansion of Ginkgo's cell therapy portfolio.
Ginkgo Bioworks (NYSE: DNA), a company focused on cell programming and biosecurity, announced that its Co-Founder and CEO Jason Kelly will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 16, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A webcast link and replay will be available on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has been awarded a $9.4 million subcontract in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices for treating hormone disorders under ARPA-H's REACT program. The BIO-INSYNC project focuses on creating implantable devices that can produce therapeutic molecules and monitor disease biomarkers in real-time for at least one year after implantation.
The initiative will initially target thyroid disorders, developing systems to measure thyroid hormone levels and produce required doses. Patients and healthcare providers will be able to monitor and control the treatment via smartphone. The project combines Ginkgo's expertise in mammalian cell and iPSC engineering with Carnegie Mellon's bioelectronics capabilities, along with researchers from the University of Pittsburgh, University of Florida, and UC Santa Cruz.
Ginkgo Bioworks (NYSE: DNA) reported Q3 2024 financial results with total revenue of $89 million, up 61% year-over-year, including a $45 million non-cash revenue from deferred revenue release. Excluding this impact, revenue was $44 million, down 21%. Cell Engineering revenue decreased 20% to $30 million, while Biosecurity revenue fell to $14 million. The company reported a Loss from operations of $(55) million and Adjusted EBITDA of $(20) million. Ginkgo updated its 2024 guidance to $215-235 million in total revenue. The company achieved cost reductions through restructuring, estimating over $85 million in annualized savings by mid-2025.
Ginkgo Bioworks (NYSE: DNA) has successfully completed the first milestone in its partnership with Merck focused on improving biologic manufacturing. The achievement triggers a $9 million cash research milestone payment to Ginkgo. The collaboration will now proceed to its second stage, continuing efforts to enhance production processes. Ginkgo will leverage its strain engineering, high-throughput screening, and process development capabilities to support this pharmaceutical partnership.
Ginkgo Bioworks (NYSE: DNA) has scheduled its third quarter 2024 business performance presentation and Q&A session for Tuesday, November 12, 2024, at 5:30 p.m. ET, after market close. The presentation will cover results for the quarter ended September 30, 2024. Investors can access the webcast through Ginkgo's investor relations website, where a replay will also be available. Questions can be submitted beforehand via X (using #GinkgoResults) or email.
Ginkgo Bioworks (NYSE: DNA) has announced a new partnership with NOVUS International to develop advanced feed additives for the animal agriculture industry. The collaboration aims to create more efficient enzymes that can be produced cost-effectively using Ginkgo Enzyme Services. This initiative is designed to address the challenges faced by the agricultural sector, including rising feed costs and tightening margins.
The partnership focuses on improving the health and performance of livestock, particularly chickens, pigs, and cows. By leveraging Ginkgo's research innovation platform and NOVUS's animal feed application knowledge, the companies aim to bring cutting-edge technologies to market that enhance the sustainability and efficiency of animal production systems. This collaboration is expected to support producers in delivering nutritious and affordable animal products to consumers while addressing economic, environmental, and regulatory challenges.
Ginkgo Bioworks (NYSE: DNA) has launched Ginkgo Datapoints, a service designed to enhance AI model training in biology. This initiative aims to generate large, high-quality biological datasets quickly and cost-effectively. The service includes products for protein characterization and functional genomics, with the latter being the flagship offering. Ginkgo Datapoints addresses key challenges in AI model training for biology, including data availability, quality, and uniformity.
The service offers flexibility, customizability, scalability, and speed, delivering millions of data points in as little as three weeks. It leverages Ginkgo's automation and data management infrastructure to provide cost-efficient, high-quality data with volume discounts for larger datasets. Customers retain ownership of the generated data through fee-for-service pricing, making it an attractive option for various entities in the biotech and tech industries.
Ginkgo Bioworks (NYSE: DNA) has launched two new offerings to accelerate drug development, building on its partnership with Google Cloud. The first is a protein large language model (LLM) built with Google Cloud Consulting, designed to give researchers and companies insights from Ginkgo's private data. The second is a model API, allowing direct access to biological AI models.
The protein LLM, one of the first of its kind in the industry, will be available on Google Cloud's Vertex AI Model Garden. The model API is already publicly accessible on Ginkgo's website. These tools aim to streamline research pipelines, optimize lead identification, and bring medicines to market faster. Ginkgo's first model, ginkgo-AA-0-650m, is trained on over 2 billion proprietary protein sequences.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
What are the main segments of Ginkgo Bioworks?
What recent acquisitions has Ginkgo Bioworks made?
What is Biofab1?
Who are Ginkgo Bioworks' partners?
What is Ginkgo's role in biosecurity?
How is Ginkgo integrating AI in its operations?
What financial challenges is Ginkgo facing?
How can I stay updated with Ginkgo Bioworks' latest news?
When is Ginkgo's next financial update?
